Why the study?
Circulating levels of the targets of novel lipid-lowering drugs (PCSK9, ANGPTL3, and Lp(a)) have not been fully investigated in cancers, prompting evaluation of their potential role.
Are circulating levels of PCSK9, ANGPTL3, and Lp(a) altered in women with stage III breast cancer compared to those with benign or premalignant breast lesions?
Comparison
Stage III breast cancer vs premalignant or benign breast lesions
Design
Age-matched case-control study
Key result
PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign lesion (95.9 vs 78.5 ng/mL).
Authors
Loading...
PCSK9 elevation was associated with stage III breast cancer; leaves open any therapeutic implications for PCSK9 inhibitors.
Case-Control (n=46)
No
Are circulating levels of PCSK9, ANGPTL3, and Lp(a) altered in women with stage III breast cancer compared to those with benign or premalignant breast lesions?
Absolute Event Rate: 95.9% vs 78.5%
p-value: p=<0.05
Circulating PCSK9 levels are elevated in women with stage III breast cancer compared to those with benign lesions, suggesting a potential link between PCSK9 and breast cancer severity.
Chong et al. (2022) conducted a case-control in Breast cancer (n=46). Stage III breast cancer vs. Benign breast lesion was evaluated on Circulating PCSK9 levels (ng/mL) (p=<0.05). PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign lesion (95.9 vs 78.5 ng/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: